San Rafael, CA, United States of America

Yoshio Hosobuchi


Average Co-Inventor Count = 1.6

ph-index = 2

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 1984-1987

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Yoshio Hosobuchi

Introduction

Yoshio Hosobuchi is a notable inventor based in San Rafael, CA (US). He has made significant contributions to the field of medical treatments, particularly in addressing cerebral ischemia. With a total of 2 patents, his work has the potential to impact the lives of many patients suffering from neurological conditions.

Latest Patents

One of his latest patents is a method of treating cerebral ischemia. This innovative approach involves administering an opioid peptide, with a particular preference for dynorphin or dynorphin-related peptides in either acid or amidated form. The practice of this invention is useful in prolonging survival for patients affected by this condition. Another significant patent focuses on the reversal of ischemic neurologic deficits in humans. This method provides effective treatments for stroke victims by administering an effective amount of the opiate antagonist naltrexone.

Career Highlights

Throughout his career, Yoshio Hosobuchi has worked with various institutions, including the University of California. His research and inventions have contributed to advancements in medical science, particularly in the treatment of stroke and ischemic conditions.

Collaborations

Yoshio has collaborated with notable individuals in his field, including Nancy M Lee and Horace H Loh. Their combined expertise has likely enhanced the quality and impact of his research.

Conclusion

Yoshio Hosobuchi's innovative work in the medical field demonstrates his commitment to improving patient outcomes through his inventions. His patents reflect a deep understanding of complex medical issues and a dedication to finding effective solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…